- Home
- Applications
- drug candidate
Refine by
Drug Candidate Product Applications
5 applications found
Several of the Navigo-created, ready-to-go Affilin molecules against solid tumor targets are currently developed as protein-drug conjugates (PDCs), by combining them to a half-life extending module and an engineered toxin-carrying moiety. Compared to notoriously difficult-to-produce and inhomogeneous Antibody-Drug Conjugates (ADCs), Affilin®-based PDCs have clear advantages. ...
ByNavigo Proteins GmbH based in Halle, GERMANY
Real-time and label-free characterization of drug candidates in living ...
Bylino Biotech AG based in Zurich, SWITZERLAND
Accurate ADME-Tox profiling of preclinical drug candidates remains a challenge. Preclinical ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies are pivotal to predicting human response. ...
ByEmulate based in Boston, MASSACHUSETTS (USA)
More than 5 million people in the United States and an estimated 50 million people worldwide are living with Alzheimer’s disease. More than 10 million people worldwide are living with Parkinson’s. Brain tumors and tumors of the central nervous system are the most common form of cancer in children under 19 and the leading cause of cancer-related deaths in children under 14 in the U.S. While antibody drugs have made great strides in cancer therapies, crossing the blood-brain barrier (BBB) and ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)
In many therapeutic areas, current treatments involve significant side effects. Combining drug compounds with affinity agents that target specific cell surface receptors can dramatically reduce off-target effects and improve treatment effectiveness. In several studies, aptamer-mediated drug delivery has reduced toxicity and improved drug performance. ...
ByBase Pair Biotechnologies, Inc. based in Pearland, TEXAS (USA)